Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Today, Sanofi and Stagecoach Performing Arts are excited to introduce a unique partnership. Selected through a UK-wide audition process, four talented teens living with autoimmune Type 1 diabetes ...

Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million deal, the companies said on Thursday, as the French drugmaker seeks to boost its neurological pipeline ...

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial to treat "smoker's lung" and lasted for the duration of the 1-year study, French drugmaker ...

UBS analyst Michael Leuchten maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of EUR93.00. The company’s shares closed last Friday at $92.88.

A little over a year ago, Pfizer changed its logo and corporate websites and today Sanofi is making the same move.

Sanofi is aiming to better unify itself with a new brand and logo, the company announced today. The new brand will encompass both vaccine arm Sanofi Pasteur and specialty care group Sanofi Genzyme.

Healthcare company Sanofi S.A. (SNY) recently revealed that it has entered into an agreement to acquire a biotechnology company, Origimm Biotechnology GmbH. The terms of the deal have not been ...

PARIS (Reuters) -French healthcare company Sanofi said on Wednesday it would buy Austrian group Origimm Biotechnology, a move that will add a potential first-in-class vaccine candidate to treat ...

Sanofi (SNYNF) has halted its venglustat clinical trial for the treatment of polycystic kidney disease as a Phase 2/3 study of the treatment did not meet its futility criteria.

PARIS (Reuters) - French drugmaker Sanofi said on Monday it would invest 400 million euros ($475.40 million) over five years in a new vaccine production site in Singapore.